MNHR Study Image


Current Research: The MNHR COVID study will determine the prevalence of COVID-19 antibodies in pregnant /recently delivered women in 8 Global Network sites (in DRC, Kenya, Zambia, Bangladesh, India [2 sites], Pakistan and Guatemala) and its association with maternal, fetal and neonatal outcomes. Additionally, we aim to explore knowledge, attitudes and prevention practices regarding COVID-19 during pregnancy.

Over a 24-month period, approximately 170 women per month from each site will be asked to complete a questionnaire and provide a blood sample at or near delivery, which will be tested for COVID-19 antibodies; quality control will be provided by RTI. Through the data that are routinely collected by the Global Network’s Maternal Newborn Health Registry (MNHR), we will evaluate fetal, neonatal, and maternal outcomes.

This study will help to understand the extent of the infection in the population, and the unknown impact of both symptomatic and asymptomatic infection on the pregnancy outcomes, and provide answers to questions related to COVID-19 infection in pregnant women especially from LMICs where access to authentic information is limited. The Global Network’s COVID-19 study will be an important contribution to the understanding of the prevalence of COVID-19 among pregnant women as well as the association between COVID-19 and pregnancy outcomes in LMICs.